The plain answer in this quarter’s sermorelin news is that there was no new human trial or sermorelin-specific FDA decision between June and September 18, 2026. The July compounding panel reviewed seven other peptides, not sermorelin. The evidence and regulatory history therefore still carry the answer: Geref left the market years ago, today’s prescriptions are compounded, and the adult research remains small and old.
As of September 18, 2026, the day this article was written, the newest sermorelin paper was a review rather than a clinical trial, and the current federal compounding records had not changed sermorelin’s standing.
Changelog
September 18 — the two federal compounding records still say different things. FDA’s 503A nominations record, updated May 14, 2026, does not list sermorelin in Category 1, 2, or 3. The separate 503B nominations record, updated March 21, 2025, lists sermorelin acetate in Category 1. Category 1 means the bulk substance—the active ingredient a pharmacy starts with—is still under evaluation. It is not a product approval. Section 503A covers patient-specific pharmacy compounding; 503B covers outsourcing facilities. Mixing those documents is how the online answers get tangled.
A Category 1 nomination is also not the final 503B bulks list. It describes an interim enforcement policy while FDA evaluates the substance, and the document says other requirements still apply. That is a narrower fact than either “approved” or “unavailable.”
July 23–24 — sermorelin was not on the compounding panel’s agenda. FDA’s meeting page names seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, and Epitalon. A vote about one of those substances did not change sermorelin’s status.
June 18 — a new review mapped the limits; it did not add a human trial. A Frontiers in Endocrinology review described adult evidence as limited and largely indirect. A second review appearing in a July journal issue reached a similar conclusion for performance use (Coutinho et al., 2026). Neither paper tested sermorelin in people.
What this sermorelin news does not change
Sermorelin is GHRH(1-29)-amide, the 29-amino-acid active fragment of growth hormone-releasing hormone. In plain English, it sends a short signal to a functioning pituitary gland to release growth hormone. It is not growth hormone itself.
The strongest direct clinical evidence belongs to pediatric growth-hormone deficiency, not adult wellness. A 1996 open-label study treated 110 children, with 86 included in the efficacy analysis. Average growth velocity rose from 4.1 centimeters a year at baseline to 8.0 at six months and 7.2 at twelve months (Thorner et al., Journal of Clinical Endocrinology & Metabolism). That study supported the old pediatric use; it cannot answer claims about sleep, body composition, or healthy aging in adults. It also lacked a placebo group, so the result belongs to that treated child cohort rather than a general promise about the molecule.
The adult study people often reach for was much smaller. Eleven healthy men ages 64 to 76 received nightly GHRH(1-29) for six weeks. Overnight growth-hormone release increased, but IGF-1—a downstream blood marker—did not, and neither weight nor body composition changed (Vittone et al., Metabolism). The sermorelin clinical-trials guide owns the full evidence history. The honest September update is that no newer human trial displaced it.
Why CJC-1295 with ipamorelin is a different option
CJC-1295 also acts on the GHRH pathway, while ipamorelin adds a second growth-hormone-secretagogue signal. That makes the combination related to sermorelin, but not interchangeable with it. Formulation and duration matter, and a mechanism is not proof of a better outcome. The sermorelin versus CJC-1295 comparison explains those differences without turning them into a dosing schedule.
That is the reason the related product belongs here: it gives a provider another pathway to discuss, not a shortcut around an individual review.
Where approval and compounding stand
There is no FDA-approved sermorelin product currently marketed—Geref was approved in 1997 and withdrawn in 2009—and the compounded formulation offered here is not FDA-approved. FDA later determined that Geref was not withdrawn for reasons of safety or effectiveness; its 2013 Federal Register notice says the sponsor had discontinued the products and requested withdrawal.
That history is easy to flatten into the wrong answer. The reasons sermorelin is not FDA-approved today separates the old Geref approvals from today’s compounded prescriptions. The 503A and 503B category documents concern bulk substances used in compounding. They do not restore Geref, approve a new sermorelin product, or settle whether treatment fits one person.
Regulatory status is one part of a clinical decision, not a marketing gate. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
What a provider considers now
The review starts with the reason for the request and whether the pituitary can respond to a GHRH signal. It also covers symptoms, laboratory history, current medicines, and conditions that could make changing the growth-hormone and IGF-1 pathway a poor fit. The old child studies and the small adult studies are context, not a personal forecast.
The prescriber sets the formulation and dose. At Promise, a licensed provider reviews every request and not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses it, creating a record of what is in the vial and who is accountable for it. That route also gives the patient a clinician and pharmacy to contact if the response or label is unclear.
What to watch next
A real change in the next edition would be a new human trial, an updated FDA nominations document, a sermorelin item on a public advisory-committee agenda, or a new marketed product. Until one of those happens, the careful reading is simple: the mechanism is established, the old pediatric evidence is real, and evidence for the adult goals now attached to sermorelin remains limited.